Tag: AI

siemens-opens-first-mindsphere-application-center-in-canada-to-accelerate-digitalization-of-energy-and-infrastructure

Siemens opens first MindSphere Application Center in Canada to accelerate digitalization of energy and infrastructure

leading-cybersecurity-provider,-esentire,-honored-with-a-5-star-rating-in-the-2021-crn-partner-program-guide

Leading Cybersecurity Provider, eSentire, Honored with a 5-Star Rating in the 2021 CRN® Partner Program Guide

predictmedix-inc.-announces-engagement-of-investment-banking-firm-kingswood-capital-markets

Predictmedix Inc. Announces Engagement of Investment Banking Firm Kingswood Capital Markets

virtual-meeting-software-market-predicted-to-reach-$57.23-billion-by-2027,-claims-allied-market-research

Virtual Meeting Software Market Predicted to Reach $57.23 Billion by 2027, Claims Allied Market Research

biosig-issues-shareholder-letter-with-corporate-update-on-recent-achievements-and-anticipated-milestones-for-2021

BioSig Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021

analytixinsight-announces-investopro-has-received-regulatory-approval-as-online-financial-broker

AnalytixInsight Announces InvestoPro Has Received Regulatory Approval as Online Financial Broker

inuvo’s-intentkey-artificial-intelligence-technology-solution-beats-client-kpi-by-200%-in-state-sponsored-marketing-campaign

Inuvo’s IntentKey Artificial Intelligence Technology Solution Beats Client KPI by 200% in State Sponsored Marketing Campaign

standard-named-winner-in-2021 artificial-intelligence-excellence-awards

Standard Named Winner in 2021 Artificial Intelligence Excellence Awards

philips-partners-with-orbita-to-develop-conversational-voice-and-chatbot-applications-to-complement-its-telehealth-solutions

Philips partners with Orbita to develop conversational voice and chatbot applications to complement its telehealth solutions

lilly,-vir-biotechnology-and-gsk-announce-positive-topline-data-from-the-phase-2-blaze-4-trial-evaluating-bamlanivimab-with-vir-7831-in-low-risk-adults-with-covid-19

Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19